Chronic Granulomatous Disease: A Multicentre Study of DHR Flow Cytometry Results and Clinical Correlations in Malaysia
Main Article Content
Abstract
Background: Chronic granulomatous disease (CGD) is an inherited primary immunodeficiency disease that results from a defect in one of the respiratory burst oxidases (NADPH oxidase) genes that form its components. The diagnostic laboratory assessment for CGD includes evaluation of NADPH oxidase function in neutrophils, using DHR test. The main objective of this project is to develop an internal reference range by determining the relative proportion of oxidising cells percentages and the mean fluorescence intensity (MFI) for complete interpretation of the test results and more accurate results.
Methods: A retrospective analysis was conducted on 107 individuals referred for DHR testing from Institut Perubatan dan Pergigian Termaju (IPPT) and Hospital Universiti Sains Malaysia (HUSM). Purposive sampling was employed. Logistic regression was used to explore relationships between groups and test parameters, and receiver operating characteristic curve (ROC) analysis assessed test precision.
Results: From our findings, the optimum cut-point for IPPT to differentiate CGD patients from healthy group with fMLP% was 0.26%, and FMLP MFI was 9.15, PMA% was 58.70%, and PMA MFI was 50.00. For the HUSM data, the best possible cut-point for fMLP% was 3.86%, FMLP MFI was 999.50, PMA% was 45.69%, and PMA MFI was 1130.50. The parameters showed a good analytical ability since all the area under the curve (AUC) values were significant (P > 0.5).
Conclusion: This study confirmed the importance of developing an internal reference range for accurate diagnosis of CGD. This data showed a difference between two centres in terms of test results and cut-points, highlighting the need for standardised reference ranges in diagnostic testing.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Chiriaco M, Salfa I, Di Matteo G, Rossi P, Finocchi A. Chronic granulomatous disease: clinical, molecular, and therapeutic aspects. Pediatr Allergy Immunol. 2016;27(3):242–253. https://doi.org/10.1111/pai.12527
Köker MY, Camcıoğlu Y, van Leeuwen K, Kılıç SŞ, Barlan I, Yılmaz M, et al. Clinical, functional, and genetic characterization of chronic granulomatous disease in 89 Turkish patients. J Allergy Clin Immunol. 2013;132(5):1156–1163.e5. https://doi.org/10.1016/j.jaci.2013.05.039
Matute JD, Arias AA, Wright NAM, Wrobel I, Waterhouse CCM, Xing JL, et al. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood. 2009;114(15):3309–3315. https://doi.org/10.1182/blood-2009-07-231498
Holland SM. Chronic granulomatous disease. Hematol Oncol Clin North Am. 2013;27(1):89–99. https://doi.org/10.1016/j.hoc.2012.11.002
Gennery AR, Holland SM. Primary immunodeficiencies: Not just paediatric diseases. Eur Respir J. 2015;45(6):1521–1523. https://doi.org/10.1183/09031936.00020215
Fayyaz F, Khashayar K, Nirouei M, Tavakol Z, Tavakol M. Chronic granulomatous disease (CGD): epidemiology, pathogenesis, clinical phenotype, diagnosis, prognosis and management. Immunol Genet J. 2020;3(3):16–29.
Roos D. Chronic granulomatous disease. Br Med Bull. 2016;118(1):50–63. https://doi.org/10.1093/bmb/ldw009
Scheffler-Mendoza SC, Yamazaki-Nakashimada MA, Olaya-Vargas A, Morin-Contreras A, Juárez-Echenique JC, Alcántara-Ortigoza MA, et al. Successful stem cell transplantation in a child with chronic granulomatous disease associated with contiguous gene deletion syndrome and complicated by macrophage activation syndrome. Clin Immunol. 2014;154(2):112–115. https://doi.org/10.1016/j.clim.2014.07.004
Martinez CA, Shah S, Shearer WT, Rosenblatt HM, Paul ME, Chinen J, et al. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol. 2012;129(1):176–183. https://doi.org/10.1016/j.jaci.2011.10.005
Arnold DE, Heimall JR. A review of chronic granulomatous disease. Adv Ther. 2017;34(12):2543–2557. https://doi.org/10.1007/s12325-017-0636-2
Mohd L, Latiff AHA, Ismail IH, Noah RM, Wahab AA, Hamid IJA, et al. Clinical and demographic pattern of chronic granulomatous disease (CGD) from a multicenter perspective: Malaysia’s experience over 26 years. Allergy Asthma Clin Immunol. 2021;17(1):50. https://doi.org/10.1186/s13223-021-00551-4
Battersby AC, Cale CM, Goldblatt D, Gennery AR. Clinical manifestations of disease in X-linked carriers of chronic granulomatous disease. J Clin Immunol. 2013;33(8):1276–1284. https://doi.org/10.1007/s10875-013-9939-5
Wilkinson IB, Raine T, Wiles K, Goodhart A, Hall C, O’Neill H. Reference intervals, etc. Oxford Handb Clin Med. 2017;29:750–757. https://doi.org/10.1093/med/9780199689903.003.0017
Zimmerman O, Abraham R, Bednarski J, Cooper M. Interpretation of DHR results for chronic granulomatous disease (CGD): improving diagnostic accuracy. Ann Allergy Asthma Immunol. 2018;121(5):S112. https://doi.org/10.1016/j.anai.2018.09.368
Meshaal S, El Hawary R, Abd Elaziz D, Alkady R, Galal N, Boutros J, et al. Chronic granulomatous disease: review of a cohort of Egyptian patients. Allergol Immunopathol. 2015;43(3):279–285. https://doi.org/10.1016/j.aller.2014.11.003
Movahedi Z, Norouzi S, Mamishi S, Rezaei N. BCGiosis as a presenting feature of a child with chronic granulomatous disease. Braz J Infect Dis. 2011;15(1):83–86. https://doi.org/10.1590/S1413-86702011000100016
Blancas-Galicia L, Santos-Chávez E, Deswarte C, Mignac Q, Medina-Vera I, León-Lara X, et al. Genetic, immunological, and clinical features of the first Mexican cohort of patients with chronic granulomatous disease. J Clin Immunol. 2020;40(3):475–493. https://doi.org/10.1007/s10875-020-00750-5
Güngör T, Chiesa R. Cellular therapies in chronic granulomatous disease. Front Pediatr. 2020;8:327. https://doi.org/10.3389/fped.2020.00327
Suliaman F, Amra N, Sheikh S, Almuhsen S, Alsmadi O. Epidemiology of chronic granulomatous disease of childhood in Eastern Province, Saudi Arabia. Pediatr Asthma Allergy Immunol. 2009;22(1):21–26. https://doi.org/10.1089/pai.2008.0513
Jirapongsananuruk O, Malech HL, Kuhns DB, Niemela JE, Brown MR, Anderson-Cohen M, et al. Diagnostic paradigm for evaluation of male patients with chronic granulomatous disease, based on the dihydrorhodamine 123 assay. J Allergy Clin Immunol. 2003;111(2):374–379. https://doi.org/10.1067/mai.2003.58
Ekelund S. ROC curves—what are they and how are they used? Point Care. 2012;11(1):16–21. https://doi.org/10.1097/POC.0b013e318246a642
Mayo Clinic Laboratories. DHR - overview: dihydrorhodamine flow cytometric test, blood. [Internet]. Mayo Foundation for Medical Education and Research; 1995–2025. Available at: https://www.mayocliniclabs.com/test-catalog/overview/62764#Clinical-and-Interpretive
Kelimeler A. Anahtar Kelimeler: Kronik granülomatöz hastalık, dihidrorhodamin testi, referans değerler. Selcuk Univ Med Fac Konya. 2019;123(1):611–616.
El-Ghoneimy DH, Hesham M, Hasan R, Tarif M, Gouda S. The behavior of neutrophil extracellular traps and NADPH oxidative activity in pediatric systemic lupus erythematosus: relation to disease activity and lupus nephritis. Clin Rheumatol. 2019;38(9):2585–2593. https://doi.org/10.1007/s10067-019-04547-9